On March 11, 2024, Sinqi Pharmaceutical Co., Ltd. officially announced that its undependetly developed drug, Xingqi Meioupin® 0.01% Atropine Sulfate Eye Drops indicated for the slowing of the myopia progression in children aged 6 to 12 years from -1.00D to -4.00D (astigmatism ≤1.50D, anisometropia ≤1.50D). Currently, there are no similar products approved for myopia-related indications in China. Xingqi Meioupins® adopts the exclusive MYOSTAFORT® innovative technology, the preparation is more stable, the eye drops are more comfortable, and no preservatives are added, bringing safety, effectiveness, convenience, accessibility and reasonable price to the vast number of myopic children and adolescents in China.

In China, there is a high incidence of myopia, low age of onset, and a high proportion of high-grade myopia. Myopia prevention and control has become a national policy.

In 2021, the National Health Commission announced: In 2020, our domestic overall myopia rate among children and adolescents was 52.7%, including 14.3% for 6-year-old children, 35.6% for primary school students, 71.1% for junior high school students, and 80.5% for high school students, of which the proportion for high myopia was nearly 10%. According to related data, without effective control measures, the myopia rate among children and adolescents aged 3-19 is expected to reach 84% in 2050, and the rate of high myopia will reach 20%. High myopia can easily lead to a variety of serious complications, such as cataracts, retinal detachment, and glaucoma, which are blinding eye diseases, and can lead serious resulting social and economic burdens.

Studies have confirmed that myopia in school-age children progresses to 75 to 100 degrees per year, and the progress gradually slows down with age. Myopia occurs at a young age and progresses at a quick pace. Without early intervention, the risk of progression to high myopia increases. The WHO myopia report shows that if we can reduce the progression of myopia rate by 50%, high myopia can be reduced by 90%. In order to control blinding complications occurrence of high myopia, measures are needed in each process of myopia occurrence and development from non-myopia to myopia, myopia to moderate myopia, and high myopia to pathological changes. Therefore, experts proposed the concept of myopia management: eye health management for children and adolescents who have not developed myopia to prevent myopia; for children and adolescents who have developed myopia, personalized correction and prevention measure are adopted to control myopia using scientific education and standardized diagnosis and treatment; for children who already have high/pathological myopia, complications and visual damage prevention are needed. The ultimate goal of myopia management is to prevent the occurrence and development of myopia during the "golden period" of myopia management in children, thereby reducing the final level of myopia (that is, reducing the incidence of moderate and high myopia), avoiding moderate and high myopia, and thus reducing the risk of myopia and the related complications due to blinding myopia.

0.01% atropine eye drops are the basic medication for myopia management in children and adolescents

Atropine is a non-selective M receptor blocker, also known as an anticholinergic drug. It can non-selectively block the interaction between acetylcholine and various M receptor subtypes, and c comprehensively prevent and control the progression of myopia through multiple mechanisms. Atropine has been used to control the progression of myopia for nearly a hundred years. The drug plays a dominant role in clinical research and clinical practice of myopia control. It is currently the only drug that has been verified by evidence-based medicine to prevent and control myopia and is recommended for use by IMI Clinical Myopia Management, Guidelines reports, appropriate technical guidelines for the prevention and control of myopia in children and adolescents, white papers on myopia management, and many other domestic and foreign guidelines and consensus recommendations.

0.01% atropine eye drops have been used to prevent and control myopia in Singapore, Japan, India, Hong Kong, China, and Taiwan for nearly 20 years. It has been verified by tens of thousands of myopic children for many years of real-world clinical use and has good safety. 0.01% atropine eye drops have a good effect in slowing down the progression of myopia. It can slow down the progression of myopia by 60% as a mono-therapy, and has minimal rebound effect after drug withdrawal. It also has a cumulative effect on myopia control. It is a reasonable concentration for myopia management in children and adolescents with myopia at this stage. It can be used flexibly as in conjunction with optical control methods to bring into play the synergistic mechanism of drugs and optics. The initial combination with defocus glasses can delay the growth of the axial length by 77%, and the initial combination with OK lenses can further delay the growth of the axial length by 28%. The use of 0.01% atropine eye drops is simple and flexible. Used once a night, one drop at a time, this drug is more time- and economic-effective and highly accepted by parents. It is the basic medication for myopia management in children and adolescents.

Xingqi Meioupin® was approved to benefit more myopic children

The approval of Xingqi Meioupin® can enable more myopic children to obtain convenient and accessible myopia control methods, reduce the final degree of myopia, help achieve the overall goal of comprehensive prevention and control of children and adolescents, and jointly protect children's eyes.

https://news.yaozh.com/archive/42216.html